Loading...
Market
What will the next major study on GLP-1 drugs and cancer risk in Type 2 diabetes patients show by July 31, 2025?
2
Resolution / Starting Odds
Confirms current findings • 25%
Shows no significant change • 25%
Shows increased risk • 25%
Shows reduced risk but less than current findings • 25%
Publication in a peer-reviewed medical journal
Story
Study Finds Ozempic, Wegovy Lower Cancer Risk in Type 2 Diabetes Patients by 10 out of 13
Jul 5, 2024, 05:09 PM
A new study has found that GLP-1 drugs, including Ozempic and Wegovy, significantly reduce the risk of cancer in patients with type 2 diabetes. The retrospective cohort study, which analyzed electronic health records of approximately 1.65 million people over 15 years, revealed that patients on GLP-1 medications had a lower risk for 10 out of 13 obesity-related cancers compared to those on insulin therapy. The findings, published Friday in JAMA Network Open, were based on data from 113 million US patients and suggest a promising alternative for reducing cancer risk in diabetic patients.
View original story
Similar markets
Diabetes Management • 25%
Weight Loss • 25%
Addiction Treatment • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Alcohol Intoxication • 25%
Opioid Overdose • 25%
Heroin Overdose • 25%
Other • 25%
Significant reduction • 25%
Moderate reduction • 25%
No significant change • 25%
Increase in events • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
Trial discontinued • 25%